3 results
Approved WMOWill not start
To determine the performance of CardioFit* for the treatment of Class II-IV Heart Failure patients with preserved left ventricular function
Approved WMORecruiting
In this study, we want to learn more about the effect and safety of Ceralasertib plus Durvalumab on the inhibition of tumour growth, and also to better understand NSCLC and associated health problems.We compare the effect and safety of Ceralasertib…
Approved WMOCompleted
The main objectives of the trial are to:• evaluate the safety of venetoclax monotherapy.• determine dose limiting toxicities (DLT) and the recommended Phase 2 dose (RPTD) of venetoclax monotherapy.• assess the pharmacokinetics (PK) of venetoclax…